Portal de Periódicos da CAPES

Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials

2023; Elsevier BV; Volume: 5; Issue: 11 Linguagem: Inglês

10.1016/s2665-9913(23)00241-2

2665-9913

Felice Rivellese, Alessandra Nerviani, Giovanni Giorli, Louise Warren, Edyta Jaworska, Stefano Bombardieri, Myles Lewis, Frances Humby, Arthur G. Pratt, Andrew Filer, Nagui Gendi, Alberto Cauli, Ernest Choy, Iain B. McInnes, Patrick Durez, Christopher J Edwards, Maya H Buch, Elisa Gremese, Peter C. Taylor, Nora Ng, Juan D. Cañete, Sabrina Raizada, Neil D McKay, Deepak R. Jadon, Pier Paolo Sainaghi, Richard Stratton, Michael R. Ehrenstein, Pauline Ho, Joaquim Polido‐Pereira, Bhaskar Dasgupta, Claire Gorman, James Galloway, Hector Chinoy, Désirée van der Heijde, Peter Sasieni, Anne Barton, Costantino Pitzalis, Ahmed S Zayat, Ana Rita Marinho Machado, Andrea Cuervo, Arti Mahto, Cankut Çubuk, Charlotte Rawlings, Chijioke H Mosanya, Christopher D. Buckley, Chris Holroyd, Debbie Maskall, Francesco Carlucci, Georgina Thorborn, Gina Tan, Gloria Lliso-Ribera, Hasan Rizvi, Joanna Peel, João Eurico Fonseca, John D. Isaacs, Julio Ramírez, Laurent Méric de Bellefon, Liliane Fossati-Jimak, Mary Ng’endo Githinji, Mattia Congia, Neal L. Millar, Nirupam Purkayastha, Raquel Celis, Rakhi Seth, Rebecca Hands-Greenwood, Robert Landewé, Simone Perniola, Stefano Alivernini, Stefano Marcia, Stefano Marini, Stephen Kelly, Vasco C. Romão,

Toxin Mechanisms and Immunotoxins

Despite highly effective targeted therapies for rheumatoid arthritis, about 40% of patients respond poorly, and predictive biomarkers for treatment choices are lacking. We did a biopsy-driven trial to compare the response to rituximab, etanercept, and tocilizumab in biologic-naive patients with rheumatoid arthritis stratified for synovial B cell status.